Physician

Adam Jordan Goldrich, MD

According to 2025 Medicare claims, Adam Goldrich, MD (NPI: 1912292517) practices hematology/oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Anne Arundel, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21401-9998. Goldrich is affiliated with the Mission Health Partners, LLC (ACO ID: A2591) and Aledade 61 WA CCCN CHC MSSP Enhanced (ACO ID: A4777), participating under the MSSP model.

Goldrich's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 666 traditional Medicare patients, billed 227,421 HCPCS/CPT codes, and received $4,940,638 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,625 prescription claims across 225 beneficiaries totaling $2,324,040 in drug costs, led by Tagrisso (Osimertinib Mesylate). 2023 DME data shows 109 claims. Open Payments data shows 12 records totaling $289. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $83,246 to $4,940,638. Similarly, Part D prescription costs have risen steadily, from $29,832 to $2,324,040. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $696 to $9,249.